Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 554-564

  Slavik, Roger ^a   Herde, Adrienne Müller ^a   Bieri, Daniel ^a   Weber, Markus ^b   Schibli, Roger ^a   Krämer, Stefanie D ^a   Ametamey, Simon M ^a   Mu, Linjing ^c,d  

^a ETH ZURICH   (Switzerland)

^b Neuromuscular Diseases Unit/ALS Clinic   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d NUK D2 ^*  (Switzerland)

Author keywords

Autoradiography; Cannabinoid receptor type 2; Neuroinflammation; Positron emission tomography; Radiolabeling

Indexed keywords

1 (2 ETHOXYETHYL) 8 METHOXY 4 OXO N PHENETHYL 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; 1 (2 ETHOXYETHYL) N (3 HYDROXYADAMANTAN 1 YL) 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; 1 BUTYL N (CYCLOPROPYLMETHYL) 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; 1 BUTYL N CYCLOPENTYL 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; 4 OXO QUINOLINE C 11 DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; LIPOPOLYSACCHARIDE; N (1 ADAMANTYL) 1 (2 ETHOXYETHYL) 8 HYDROXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; N (1 ADAMANTYL) 1 (2 ETHOXYETHYL) 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; N (1 ADAMANTYL) 1 BUTYL 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; N (TERT BUTYL) 1 (3 FLUOROPROPYL) 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; N (TERT BUTYL) 1 BUTYL 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXAMIDE C 11; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ADAMANTANE; CARBON; QUINOLONE DERIVATIVE; RS-016;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; GENE EXPRESSION; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; LIPOPHILICITY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; RADIOACTIVITY; RADIOCHEMISTRY; RAT; SPINAL CORD; SPLEEN; SPLEEN FUNCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; INFLAMMATION; MALE; METABOLISM; MOLECULAR IMAGING; MOUSE; NERVOUS SYSTEM DISEASES; PROCEDURES; TISSUE DISTRIBUTION; WISTAR RAT;

ADAMANTANE; ANIMALS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MALE; MICE; MOLECULAR IMAGING; MOLECULAR STRUCTURE; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; QUINOLONES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; TISSUE DISTRIBUTION;

EID: 84921358298     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.01.028     Document Type: Article

References (35)

1. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, T.I. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature 346 (1990) 561e564.
2. S. Munro, K.L. Thomas, M. Abu-Shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature 365 (1993) 61e65.
3. K. Mackie, Distribution of cannabinoid receptors in the central and peripheral nervous system, Handb. Exp. Pharmacol. (2005) 299e325.
4. M.K. Sharma, P.R. Murumkar, A.M. Kanhed, R. Giridhar, M.R. Yadav, Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists, Eur. J. Med. Chem. 79 (2014) 298e339.
5. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, et al., Identification and functional characterization of brainstem cannabinoid CB2 receptors, Science 310 (2005) 329e332.
6. J.C. Ashton, D. Friberg, C.L. Darlington, P.F. Smith, Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study, Neurosci. Lett. 396 (2006) 113e116.
7. A. Brusco, P. Tagliaferro, T. Saez, E.S. Onaivi, Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus, Synapse 62 (2008) 944e949.
8. C. Benito, R.M. Tolon, M.R. Pazos, E. Nunez, A.I. Castillo, J. Romero, Cannabinoid CB2 receptors in human brain inflammation, Br. J. Pharmacol. 153 (2008) 277e285.
9. E.S. Onaivi, Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications, Int. Rev. Neurobiol. 88 (2009) 335e369.
10. J.L. Shoemaker, K.A. Seely, R.L. Reed, J.P. Crow, P.L. Prather, The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset, J. Neurochem. 101 (2007) 87e98.
11. Y. Yiangou, P. Facer, P. Durrenberger, I.P. Chessell, A. Naylor, et al., COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/ macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC Neurol. 6 (2006) 12.
12. D.R. Rosen, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature 364 (1993) 362.
13. L. Zinman, M. Cudkowicz, Emerging targets and treatments in amyotrophic lateral sclerosis, Lancet Neurol. 10 (2011) 481e490.
14. D.J. Graber, W.F. Hickey, B.T. Harris, Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis, J. Neuroinflamm. 7 (2010) 8.
15. L.G. Bilsland, The endocannabinoid system in amyotrophic lateral sceloris, Curr. Pharm. Des. 14 (2006) 2306e2316.
16. V. Lucchesi, T. Parkkari, J.R. Savinainen, A.M. Malfitano, M. Allara, et al., 1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor, Eur. J. Med. Chem. 74 (2014) 524e532.
17. R. Ahmad, M. Koole, N. Evens, K. Serdons, A. Verbruggen, et al., Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [C]-NE40 in healthy subjects, Mol. Imaging Biol 15 (2013) 384e390.
18. L. Mu, D. Bieri, R. Slavik, K. Drandarov, A. Muller, et al., Radiolabeling and in vitro/in vivo evaluation of N-(1-Adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor, J. Neurochem. 126 (2013) 616e624.
19. N. Evens, G.G. Muccioli, N. Houbrechts, D.M. Lambert, A.M. Verbruggen, et al., Synthesis and biological evaluation of carbon-11-And fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging, Nucl. Med. Biol. 36 (2009) 455e465.
20. A.G. Horti, Y. Gao, H.T. Ravert, P. Finley, H. Valentine, et al., Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2), Bioorg. Med. Chem. 18 (2010) 5202e5207.
21. N. Evens, C. Vandeputte, G.G. Muccioli, D.M. Lambert, V. Baekelandt, et al., Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FEGW405833 as a PET tracer for type 2 cannabinoid receptor imaging, Bioorg. Med. Chem. 19 (2011) 4499e4505.
22. C. Vandeputte, N. Evens, J. Toelen, C.M. Deroose, B. Bosier, et al., A PET brain reporter gene system based on type 2 cannabinoid receptors, J. Nucl. Med. 52 (2011) 1102e1109.
23. T. Ruhl, W. Deuther-Conrad, S. Fischer, R. Gunther, L. Hennig, et al., Cannabinoid receptor type 2 (CB2)-selective N-Aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation, Org. Med. Chem. Lett. 2 (2012) 32.
24. L. Hortala, J. Arnaud, P. Roux, D. Oustric, L. Boulu, et al., Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor, Bioorg. Med. Chem. Lett. 24 (2014) 283e287.
25. S. Pasquini, A. Ligresti, C. Mugnaini, T. Semeraro, L. Cicione, et al., Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-Affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands, J. Med. Chem. 53 (2010) 5915e5928.
26. U. Hassiepen, M. Kittelmann, Adamantyl o-glucoronide derivatives as inhibitors of dipeptidyl peptidase iv for the threatment of diabetes, WO2005012249 (A2) (2005) 1e68.
27. R.N. Waterhouse, Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents, Mol. Imaging Biol. 5 (2003) 376e389.
28. H. Pajouhesh, G.R. Lenz, Medicinal chemical properties of successful central nervous system drugs, NeuroRx 2 (2005) 541e553.
29. K.J. Valenzano, L. Tafesse, G. Lee, J.E. Harrison, J.M. Boulet, et al., Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy, Neuropharmacology 48 (2005) 658e672.
30. S. Galiegue, S. Mary, J. Marchand, D. Dussossoy, D. Carriere, et al., Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations, Eur. J. Biochem. 232 (1995) 54e61.
31. L. Qin, X. Wu, M.L. Block, Y. Liu, G.R. Breese, et al., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration, Glia 55 (2007) 453e462.
32. V.M. Showalter, D.R. Compton, B.R. Martin, M.E. Abood, Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands, J. Pharmacol. Exp. Ther. 278 (1996) 989e999.
33. Y. Cheng, W.H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol. 22 (1973) 3099e3108.
34. A.A. Wilson, L. Jin, A. Garcia, J.N. DaSilva, S. Houle, An admonition when measuring the lipophilicity of radiotracers using counting techniques, Appl. Radiat. Isot. 54 (2001) 203e208.
35. A. Müller, L. Mu, R. Meletta, K. Beck, Z. Rancic, et al., Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules, Int. J. Cardiol. 174 (2014) 503e515.